Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04949113
Title Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma (NADINA)
Recruitment Recruiting
Gender
Phase Phase III
Variant Requirements No
Sponsors The Netherlands Cancer Institute
Indications

melanoma

Therapies

Nivolumab

Ipilimumab + Nivolumab

Age Groups: adult | child | senior
Covered Countries USA


No variant requirements are available.